keyword
MENU ▼
Read by QxMD icon Read
search

American society of hematology

keyword
https://www.readbyqxmd.com/read/28526159/anticoagulation-and-neuraxial-peripheral-anesthesia
#1
REVIEW
Mudit Kaushal, Ryan E Rubin, Alan D Kaye, Karina Gritsenko
Novel anticoagulants (NAGs) have emerged as the preferred alternatives to vitamin K antagonists. In patients being considered for regional anesthesia, these drugs present a layer of complexity in the preprocedure evaluation. There are no established tests to monitor anticoagulant activity and our experience is short with these drugs. These authors believe it is important to review the relevant hematology, orthopedics, and anesthesiology literature to provide a valuable reference for the clinician who is met with these challenges...
June 2017: Anesthesiology Clinics
https://www.readbyqxmd.com/read/28518219/impact-of-the-timing-of-hepatitis-b-virus-identification-and-anti-hepatitis-b-virus-therapy-initiation-on-the-risk-of-adverse-liver-outcomes-for-patients-receiving-cancer-therapy
#2
Jessica P Hwang, Maria E Suarez-Almazor, Scott B Cantor, Andrea Barbo, Heather Y Lin, Sairah Ahmed, Mariana Chavez-MacGregor, Christian Donato-Santana, Cathy Eng, Alessandra Ferrajoli, Michael J Fisch, Peter McLaughlin, George R Simon, Gabriela Rondon, Elizabeth J Shpall, Anna S Lok
BACKGROUND: Data on the incidence of adverse liver outcomes are limited for cancer patients with chronic (hepatitis B surface antigen [HBsAg]-positive/hepatitis B core antibody [anti-HBc]-positive) or past (HBsAg-negative/anti-HBc-positive) hepatitis B virus (HBV) after chemotherapy. This study was aimed at determining the impact of test timing and anti-HBV therapy on adverse liver outcomes in these patients. METHODS: Patients with solid or hematologic malignancies who received chemotherapy between 2004 and 2011 were retrospectively studied...
May 18, 2017: Cancer
https://www.readbyqxmd.com/read/28514195/analysis-of-the-use-and-impact-of-twitter-during-american-society-of-clinical-oncology-annual-meetings-from-2011-to-2016-focus-on-advanced-metrics-and-user-trends
#3
Naveen Pemmaraju, Michael A Thompson, Ruben A Mesa, Tejas Desai
PURPOSE: The use of social media, in particular Twitter, has substantially increased among health care stakeholders in the field of hematology and oncology, with an especially sharp increase in the use of Twitter during times of major national meetings. The most attended meeting in the oncology field is the ASCO annual meeting. Little is known about the detailed metrics involved in the use, volume, and impact of Twitter during the ASCO annual meeting. METHODS: We conducted a retrospective review of tweets during the ASCO annual meetings from 2011 to 2016...
May 17, 2017: Journal of Oncology Practice
https://www.readbyqxmd.com/read/28493308/north-central-cancer-treatment-group-n0543-alliance-a-phase-2-trial-of-pharmacogenetic-based-dosing-of-irinotecan-oxaliplatin-and-capecitabine-as-first-line-therapy-for-patients-with-advanced-small-bowel-adenocarcinoma
#4
Robert R McWilliams, Nathan R Foster, Michelle R Mahoney, Thomas C Smyrk, Joseph A Murray, Matthew M Ames, L Elise Horvath, Daniel J Schneider, Timothy J Hobday, Aminah Jatoi, Jeffrey P Meyers, Matthew P Goetz
BACKGROUND: Oxaliplatin in combination with either 5-fluorouracil or capecitabine is commonly used as first-line therapy for patients with small bowel adenocarcinoma. The addition of irinotecan improves survival in other gastrointestinal tumors but at the cost of hematologic toxicity. The authors performed a phase 2 cooperative group study (North Central Cancer Treatment Group N0543, Alliance) using genotype-dosed capecitabine, irinotecan, and oxaliplatin (gCAPIRINOX), with dosing assigned based on UDP glucuronosyltransferase family 1 member A1 (UGT1A1) genotype to test: 1) whether the addition of irinotecan would improve outcomes; and 2) whether UGT1A1 genotype-based dosing could optimize tolerability...
May 10, 2017: Cancer
https://www.readbyqxmd.com/read/28462890/multiple-myeloma-clinical-updates-from-the-american-society-of-hematology-annual-meeting-2016
#5
REVIEW
Evangelos Terpos
The novel clinical data for plasma cell neoplasms (smoldering myeloma, multiple myeloma (MM) and AL-amyloidosis) that were presented in the 2016 Annual Meeting of the American Society of Hematology are summarized here. Data from large phase 3 studies for newly diagnosed MM patients who are eligible for autologous transplantation (EMN02, MRC XI and StaMINA trials) are described along with the results of phase 2 studies using novel anti-myeloma drug combinations for induction, consolidation and maintenance as first line therapy...
March 18, 2017: Clinical Lymphoma, Myeloma & Leukemia
https://www.readbyqxmd.com/read/28447341/chemotherapy-alone-versus-chemotherapy-plus-radiotherapy-for-adults-with-early-stage-hodgkin-lymphoma
#6
REVIEW
Oliver Blank, Bastian von Tresckow, Ina Monsef, Lena Specht, Andreas Engert, Nicole Skoetz
BACKGROUND: Combined modality treatment consisting of chemotherapy followed by localised radiotherapy is the standard treatment for patients with early stage Hodgkin lymphoma (HL). However, due to long- term adverse effects such as secondary malignancies the role of radiotherapy has been questioned recently and some clinical study groups advocate chemotherapy only for this indication. OBJECTIVES: To assess the effects of chemotherapy alone compared to chemotherapy plus radiotherapy in adults with early stage HL ...
April 27, 2017: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/28398280/highlights-in-gene-therapy-and-alternative-therapies-in-nonmalignant-hematology-from-the-2016-american-society-of-hematology-meeting
#7
(no author information available yet)
No abstract text is available yet for this article.
February 2017: Clinical Advances in Hematology & Oncology: H&O
https://www.readbyqxmd.com/read/28387922/characteristics-and-outcomes-of-older-patients-with-secondary-acute-myeloid-leukemia-according-to-treatment-approach
#8
Prajwal Chaitanya Boddu, Hagop M Kantarjian, Farhad Ravandi, Guillermo Garcia-Manero, Srdan Verstovsek, Elias J Jabbour, Koichi Takahashi, Kapil Bhalla, Marina Konopleva, Courtney D DiNardo, Maro Ohanian, Naveen Pemmaraju, Nitin Jain, Sherry Pierce, William G Wierda, Jorge E Cortes, Tapan M Kadia
BACKGROUND: The development of newer strategies to improve outcomes for older patients with secondary acute myeloid leukemia (s-AML) is a critical unmet need. Establishing baseline metrics for evaluating newer approaches is important. METHODS: s-AML was defined as 1 or more of the following: a history of an antecedent hematologic disorder (AHD), a diagnosis of therapy-related acute myeloid leukemia (AML), and AML with karyotype abnormalities characteristic of myelodysplastic syndrome...
April 7, 2017: Cancer
https://www.readbyqxmd.com/read/28371237/american-society-of-pediatric-hematology-oncology-aspho-palais-des-congr%C3%A3-s-de-montr%C3%A3-al-montr%C3%A3-al-canada-april-26-29-2017
#9
(no author information available yet)
No abstract text is available yet for this article.
June 2017: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/28347648/sarode-honoured-by-american-society-of-hematology
#10
EDITORIAL
G Rock, Ravi Sarode
No abstract text is available yet for this article.
March 10, 2017: Transfusion and Apheresis Science
https://www.readbyqxmd.com/read/28275115/safety-and-tolerability-of-pd-1-pd-l1-inhibitors-compared-with-chemotherapy-in-patients-with-advanced-cancer-a-meta-analysis
#11
REVIEW
Tomohiro F Nishijima, Shlomit S Shachar, Kirsten A Nyrop, Hyman B Muss
BACKGROUND: Compared with chemotherapy, significant improvement in survival outcomes with the programmed death receptor-1 (PD-1) inhibitors nivolumab and pembrolizumab and the programmed death-ligand 1 (PD-L1) inhibitor atezolizumab has been shown in several types of advanced solid tumors. We conducted a systematic review and meta-analysis to compare safety and tolerability between PD-1/PD-L1 inhibitors and chemotherapy. METHODS: PubMed and American Society of Clinical Oncology (ASCO) databases were searched 1966 to September 2016...
April 2017: Oncologist
https://www.readbyqxmd.com/read/28260821/erratum-the-hematologic-definition-of-monoclonal-gammopathy-of-undetermined-significance-in-relation-to-paraproteinemic-keratopathy-an-american-ophthalmological-society-thesis
#12
Walter Lisch, Joanna Wasielica-Poslednik, Tero Kivelä, Ursula Schlötzer-Schrehardt, Jens M Rohrbach, Walter Sekundo, Uwe Pleyer, Christina Lisch, Alexander Desuki, Heidi Rossmann, Jayne S Weiss
[This corrects the article on p. T7 in vol. 114, PMID: 28050052.].
August 2016: Transactions of the American Ophthalmological Society
https://www.readbyqxmd.com/read/28225303/initial-diagnostic-workup-of-acute-leukemia-guideline-from-the-college-of-american-pathologists-and-the-american-society-of-hematology
#13
Daniel A Arber, Michael J Borowitz, Melissa Cessna, Joan Etzell, Kathryn Foucar, Robert P Hasserjian, J Douglas Rizzo, Karl Theil, Sa A Wang, Anthony T Smith, R Bryan Rumble, Nicole E Thomas, James W Vardiman
CONTEXT: -A complete diagnosis of acute leukemia requires knowledge of clinical information combined with morphologic evaluation, immunophenotyping and karyotype analysis, and often, molecular genetic testing. Although many aspects of the workup for acute leukemia are well accepted, few guidelines have addressed the different aspects of the diagnostic evaluation of samples from patients suspected to have acute leukemia. OBJECTIVE: -To develop a guideline for treating physicians and pathologists involved in the diagnostic and prognostic evaluation of new acute leukemia samples, including acute lymphoblastic leukemia, acute myeloid leukemia, and acute leukemias of ambiguous lineage...
February 22, 2017: Archives of Pathology & Laboratory Medicine
https://www.readbyqxmd.com/read/28222220/meaningful-endpoints-for-therapies-approved-for-hematologic-malignancies
#14
B Douglas Smith, Amy E DeZern, Alex W Bastian, Brian G M Durie
BACKGROUND: Overall survival (OS) is considered the gold standard for determining treatment efficacy in oncology trials, but the relation between treatment and OS can be challenging to assess because of long study durations and the impact of subsequent therapies on outcome. Using OS can be particularly difficult for new therapies in hematologic malignancies (HMs). METHODS: This retrospective analysis was conducted to characterize the primary endpoints used to support US Food and Drug Administration (FDA) approvals for new drug or novel HM indications between January 2002 and July 2015...
May 15, 2017: Cancer
https://www.readbyqxmd.com/read/28178369/burden-of-human-metapneumovirus-infections-in-patients-with-cancer-risk-factors-and-outcomes
#15
Firas El Chaer, Dimpy P Shah, Joumana Kmeid, Ella J Ariza-Heredia, Chitra M Hosing, Victor E Mulanovich, Roy F Chemaly
BACKGROUND: Human metapneumovirus (hMPV) causes upper and lower respiratory tract infections (URIs and LRIs, respectively) in healthy and immunocompromised patients; however, its clinical burden in patients with cancer remains unknown. METHODS: In a retrospective study of all laboratory-confirmed hMPV infections treated at the authors' institution between April 2012 and May 2015, clinical characteristics, risk factors for progression to an LRI, treatment, and outcomes in patients with cancer were determined...
February 8, 2017: Cancer
https://www.readbyqxmd.com/read/28171708/a-multi-institutional-comparison-of-outcomes-of-immunosuppressed-and-immunocompetent-patients-treated-with-surgery-and-radiation-therapy-for-cutaneous-squamous-cell-carcinoma-of-the-head-and-neck
#16
Bindu V Manyam, Adam A Garsa, Re-I Chin, Chandana A Reddy, Brian Gastman, Wade Thorstad, Sue S Yom, Brian Nussenbaum, Steven J Wang, Allison T Vidimos, Shlomo A Koyfman
BACKGROUND: Patients who are chronically immunosuppressed have higher rates of cutaneous squamous cell carcinoma of the head and neck (cSCC-HN). This is the largest multi-institutional study to date investigating the effect of immune status on disease outcomes in patients with cSCC-HN who underwent surgery and received postoperative radiation therapy (RT). METHODS: Patients from 3 institutions who underwent surgery and also received postoperative RT for primary or recurrent, stage I through IV cSCC-HN between 1995 and 2015 were included in this institutional review board-approved study...
February 7, 2017: Cancer
https://www.readbyqxmd.com/read/28163560/american-society-of-hematology-annual-meeting-and-exposition
#17
Walter Alexander
Key sessions on pharmacotherapy clinical trials across a wide span of disease states, including leukemia, graft-versus-host disease, myelofibrosis, multiple myeloma, and sickle cell disease, are reviewed.
February 2017: P & T: a Peer-reviewed Journal for Formulary Management
https://www.readbyqxmd.com/read/28156530/evaluation-of-hematologist-oncologist-attributes-by-physicians-and-patients-a-survey-study
#18
Cory Patrick, Rakesh Singal, Damien Mikael Hansra
124 Background: We aim to compare what attributes are important to hematology/oncology (hem/onc) physicians (MD) and patients (pts). METHODS: IRB approval obtained. Pts and MDs at an academic tertiary care medical center were enrolled to complete a survey. Demographics include: age, gender, race, and ethnicity. Clinical info collected: cancer subtype and treating MD. Survey consisted of 5 questions assessing opinions on physician attributes. Patients were asked: "It is important that my doctor" is friendly, is empathetic, is knowledgeable, well dressed, and engaged in research...
October 9, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28152960/appropriateness-of-testing-for-heparin-induced-thrombocytopenia-in-hospitalized-patients
#19
Debasmita Saha, Gresa Ajeti, Brandon Bair, Karen Hook, Enrique Ballesteros, Lisa Holle
252 Background: Heparin induced thrombocytopenia (HIT) is a devastating thrombotic complication of heparin therapy and occurs in 0.2 to 5% of patients receiving heparin products and is a clinicopathologic diagnosis. The American Society of Hematology Guidelines, recommend the use of the "4Ts" scoring system to determine the pre-test probability of suspected cases. Also, a presumptive clinical diagnosis of HIT must be followed by immediate cessation of all forms of heparin and initiation of alternate anticoagulation...
March 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28125373/health-care-resource-utilization-and-costs-in-patients-with-chronic-myeloid-leukemia-with-better-adherence-to-tyrosine-kinase-inhibitors-and-increased-molecular-monitoring-frequency
#20
Dominick Latremouille-Viau, Annie Guerin, Patrick Gagnon-Sanschagrin, Katherine Dea, Benjamin G Cohen, George J Joseph
BACKGROUND: Frequent molecular monitoring (qPCR tests), as recommended by evidence-based monitoring guidelines, is associated with higher adherence to tyrosine kinase inhibitors (TKIs) in the management of chronic myeloid leukemia (CML); both factors have been associated with better clinical and economic outcomes. OBJECTIVES: To (a) estimate the effect of more frequent qPCR tests on health care resource utilization (HRU) and associated costs, including direct (effect of qPCR test frequency on HRU) and indirect (through TKI adherence) effects, and (b) develop an economic model applicable to multiple clinical practice scenarios...
February 2017: Journal of Managed Care & Specialty Pharmacy
keyword
keyword
12147
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"